Selective molecular biomarkers to predict biologic behavior in pituitary tumors / Luis Vicente Syro Moreno  

Público ISBD Título : Selective molecular biomarkers to predict biologic behavior in pituitary tumors Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : ENC1 gene  endocan  EZH2  FSCN1  invasion-associated genes  molecular biomarkers  neuropilin (NRP-1)  oncogene-induced senescence  pituitary adenoma  TACSTD family (EpCAM  TROP2) Resumen : Introduction: To date, several cell proliferation markers, apoptosis, vascular markers, oncogenes, tumor suppressor genes, cell cycle mediators, microRNA (miRNAs), and long noncoding RNAs (lncRNAs) have been identified to be involved in the tumorigenesis, migration, proliferation and invasiveness of pituitary adenomas. There are still no reliable morphologic markers predictive of pituitary adenoma recurrence. Recent scientific research introduced new techniques to enable us to attain new information on the genesis and biologic behavior of pituitary adenomas. Areas covered: This review covers selected, compelling and cumulative information in regards to TACSTD family (EpCAM, TROP2), neuropilin (NRP-1), oncogene-induced senescence (OIS), fascins (FSCN1), invasion-associated genes (CLDN7, CNTNAP2, ITGA6, JAM3, PTPRC and CTNNA1) EZH2, and ENC1 genes and endocan. Expert commentary: Ongoing research provides clinicians, surgeons and researchers with new information not only on diverse pathways in tumorigenesis but also on the clinical aggressive behavior of pituitary adenomas. Newly developed molecular techniques, bioinformatics and new pharmaceutical drug options are helpful tools to widen the perspectives in our understanding of the complex nature of pituitary tumorigenesis. The discovery of new molecular biomarkers can only be accomplished by continuing to investigate pituitary embryogenesis, histogenesis and tumorigenesis. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Meric A Altinoz, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2017 May;12(3):177-185. DOI (Digital Object Identifier) : 10.1080/17446651.2017.1312341 PMID : 30063456 En línea : https://www.tandfonline.com/doi/full/10.1080/17446651.2017.1312341 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4066 Selective molecular biomarkers to predict biologic behavior in pituitary tumors [documento electrónico] / Luis Vicente Syro Moreno,  . - 2017. Obra : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : ENC1 gene  endocan  EZH2  FSCN1  invasion-associated genes  molecular biomarkers  neuropilin (NRP-1)  oncogene-induced senescence  pituitary adenoma  TACSTD family (EpCAM  TROP2) Resumen : Introduction: To date, several cell proliferation markers, apoptosis, vascular markers, oncogenes, tumor suppressor genes, cell cycle mediators, microRNA (miRNAs), and long noncoding RNAs (lncRNAs) have been identified to be involved in the tumorigenesis, migration, proliferation and invasiveness of pituitary adenomas. There are still no reliable morphologic markers predictive of pituitary adenoma recurrence. Recent scientific research introduced new techniques to enable us to attain new information on the genesis and biologic behavior of pituitary adenomas. Areas covered: This review covers selected, compelling and cumulative information in regards to TACSTD family (EpCAM, TROP2), neuropilin (NRP-1), oncogene-induced senescence (OIS), fascins (FSCN1), invasion-associated genes (CLDN7, CNTNAP2, ITGA6, JAM3, PTPRC and CTNNA1) EZH2, and ENC1 genes and endocan. Expert commentary: Ongoing research provides clinicians, surgeons and researchers with new information not only on diverse pathways in tumorigenesis but also on the clinical aggressive behavior of pituitary adenomas. Newly developed molecular techniques, bioinformatics and new pharmaceutical drug options are helpful tools to widen the perspectives in our understanding of the complex nature of pituitary tumorigenesis. The discovery of new molecular biomarkers can only be accomplished by continuing to investigate pituitary embryogenesis, histogenesis and tumorigenesis. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Meric A Altinoz, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2017 May;12(3):177-185. DOI (Digital Object Identifier) : 10.1080/17446651.2017.1312341 PMID : 30063456 En línea : https://www.tandfonline.com/doi/full/10.1080/17446651.2017.1312341 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4066

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000668	AC-2017-057	Archivo digital	Producción Científica	Artículos científicos	Disponible

Biomarkers of pituitary carcinomas / Luis Vicente Syro Moreno  

Público ISBD Título : Biomarkers of pituitary carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2016 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Angiogenesis  Galectin-3  HIF-1  H-ras  Ki-67  microRNA  P27/KIP1  P53  pituitary carcinoma  telomerase Resumen : Pituitary carcinoma is a rare tumor originating from adenohypophyseal cells. Currently, diverse pathogenetic mechanisms, i.e. de novo versus malignant transformation from pituitary adenoma, remain obscure and require further investigation. During the last two decades, scientific research added new horizons not only in regards to general tumor concepts but also in next generation biomarker armamentarium that sheds light on alternate pathways in carcinogenesis. Areas covered: In this review, the impact of apoptotic and proliferative markers, angiogenesis, telomerase activity, H-ras, HIF-1, HER-2/neu, Rb gene, and microRNAs in pathogenetic mechanisms of pituitary carcinomas were revised. Expert commentary: It is becoming increasingly important for the need of standardization of new biomarkers but also for better comprehension of the diverse pathways in tumorigenesis. This can only be accomplished by tapping into the continuously expanding spectrum of new biomarkers. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2016 May;11(3):253-261. DOI (Digital Object Identifier) : 10.1080/17446651.2016.1179110 PMID : 30058931 En línea : https://www.tandfonline.com/doi/abs/10.1080/17446651.2016.1179110 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4611 Biomarkers of pituitary carcinomas [documento electrónico] / Luis Vicente Syro Moreno,  . - 2016. Obra : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Angiogenesis  Galectin-3  HIF-1  H-ras  Ki-67  microRNA  P27/KIP1  P53  pituitary carcinoma  telomerase Resumen : Pituitary carcinoma is a rare tumor originating from adenohypophyseal cells. Currently, diverse pathogenetic mechanisms, i.e. de novo versus malignant transformation from pituitary adenoma, remain obscure and require further investigation. During the last two decades, scientific research added new horizons not only in regards to general tumor concepts but also in next generation biomarker armamentarium that sheds light on alternate pathways in carcinogenesis. Areas covered: In this review, the impact of apoptotic and proliferative markers, angiogenesis, telomerase activity, H-ras, HIF-1, HER-2/neu, Rb gene, and microRNAs in pathogenetic mechanisms of pituitary carcinomas were revised. Expert commentary: It is becoming increasingly important for the need of standardization of new biomarkers but also for better comprehension of the diverse pathways in tumorigenesis. This can only be accomplished by tapping into the continuously expanding spectrum of new biomarkers. Mención de responsabilidad : Aydin Sav, Fabio Rotondo, Luis V Syro, Antonio Di Ieva, Michael D Cusimano, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2016 May;11(3):253-261. DOI (Digital Object Identifier) : 10.1080/17446651.2016.1179110 PMID : 30058931 En línea : https://www.tandfonline.com/doi/abs/10.1080/17446651.2016.1179110 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4611

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001109	AC-2016-090	Archivo digital	Producción Científica	Artículos científicos	Disponible

Improving differential diagnosis of pituitary adenomas / Carlos Esteban Builes Montaño ; Luis Vicente Syro Moreno  

Público ISBD Título : Improving differential diagnosis of pituitary adenomas Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, ; Luis Vicente Syro Moreno, Fecha de publicación : 2014 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Classification  diagnosis  familial syndrome  genetics  pathology  pituitary adenoma Resumen : Pituitary adenomas are common tumors arising in adenohypophysial cells or their precursors. For improving control of the disease an early diagnosis is important. Initially considered sporadic tumors, some of them are associated with familial syndromes and their recognition and classification is also required. Morphologically, pituitary adenomas represent a heterogeneous group of tumors with several subtypes and different clinical behavior thus a precise pathological diagnosis is crucial. The simple diagnosis of pituitary adenoma is not satisfactory and the correct classification of histological subtypes may predict aggressiveness in the majority of cases. Although considered not malignant, some of them are clinically aggressive and their recognition remains a challenge. In this paper we present the recent advances in the event of improving early recognition and differential diagnosis of pituitary tumors. Mención de responsabilidad : Luis V Syro, Carlos E Builes, Antonio Di Ieva, Aydin Sav, Fabio Rotondo, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2014 Jul;9(4):377-386. DOI (Digital Object Identifier) : 10.1586/17446651.2014.922412 PMID : 30763997 En línea : https://www.tandfonline.com/doi/abs/10.1586/17446651.2014.922412?journalCode=ier [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3801 Improving differential diagnosis of pituitary adenomas [documento electrónico] / Carlos Esteban Builes Montaño, ; Luis Vicente Syro Moreno,  . - 2014. Obra : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Classification  diagnosis  familial syndrome  genetics  pathology  pituitary adenoma Resumen : Pituitary adenomas are common tumors arising in adenohypophysial cells or their precursors. For improving control of the disease an early diagnosis is important. Initially considered sporadic tumors, some of them are associated with familial syndromes and their recognition and classification is also required. Morphologically, pituitary adenomas represent a heterogeneous group of tumors with several subtypes and different clinical behavior thus a precise pathological diagnosis is crucial. The simple diagnosis of pituitary adenoma is not satisfactory and the correct classification of histological subtypes may predict aggressiveness in the majority of cases. Although considered not malignant, some of them are clinically aggressive and their recognition remains a challenge. In this paper we present the recent advances in the event of improving early recognition and differential diagnosis of pituitary tumors. Mención de responsabilidad : Luis V Syro, Carlos E Builes, Antonio Di Ieva, Aydin Sav, Fabio Rotondo, Kalman Kovacs Referencia : Expert Rev Endocrinol Metab. 2014 Jul;9(4):377-386. DOI (Digital Object Identifier) : 10.1586/17446651.2014.922412 PMID : 30763997 En línea : https://www.tandfonline.com/doi/abs/10.1586/17446651.2014.922412?journalCode=ier [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3801

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000376	AC-2014-042	Archivo digital	Producción Científica	Artículos científicos	Disponible

Prolactinomas: diagnosis and treatment / Luis Vicente Syro Moreno  

Público ISBD Título : Prolactinomas: diagnosis and treatment Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Expert Review of Endocrinology and Metabolism Resumen : Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are classified according to size as microadenomas (10 mm diameter). The clinical features of prolactinomas most commonly result from prolactin’s effect on the gonads and breast in women and from mass effect in men. This review details the clinical features and management of patients with prolactinomas. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, Luis V Syro, Kalman Kovacs & Ricardo V Lloyd Referencia : Expert Rev Endocrinol Metab. 2012;7(2):233–41. DOI (Digital Object Identifier) : 10.1586/eem.12.4 En línea : https://www.tandfonline.com/doi/full/10.1586/eem.12.4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3605 Prolactinomas: diagnosis and treatment [documento electrónico] / Luis Vicente Syro Moreno,  . - 2012. Obra : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Expert Review of Endocrinology and Metabolism Resumen : Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are classified according to size as microadenomas (10 mm diameter). The clinical features of prolactinomas most commonly result from prolactin’s effect on the gonads and breast in women and from mass effect in men. This review details the clinical features and management of patients with prolactinomas. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, Luis V Syro, Kalman Kovacs & Ricardo V Lloyd Referencia : Expert Rev Endocrinol Metab. 2012;7(2):233–41. DOI (Digital Object Identifier) : 10.1586/eem.12.4 En línea : https://www.tandfonline.com/doi/full/10.1586/eem.12.4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3605

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000175	AC-2012-015	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 4 / 4) Por página: 25 50 100 200